High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations

Michael W. DeGregorio, David R Gandara, Walter M. Holleran, Edith A. Perez, Charles C. King, Howard G. Wold, Thomas J. Montine, Richard F. Borch

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Diethyldithiocarbamate (DDTC), a chelating agent that is a major metabolite of disulfuram, has been proposed as a potential rescue agent to reduce toxicity following high-dose cisplatin (HDCP) therapy. In the present study, we examined the pharmcologic interaction of HDCP and DDTC given as rescue therapy. Total plasma platinum and ultrafiltrate platinum pharmacokinetics and DDTC levels were determined in six patients with advanced malignancies who received a total of 11 cycles of HDCP with DDTC rescue. HDCP therapy (200 mg/m2 per cycle) consisted of 100 mg/m2 reconstituted in 250 cc 3% saline and infused over 3 h on days 1 and 8 of each 28-day cycle. DDTC rescue at a dose of 4 gm/m2 was given by an i.v. infusion (duration 1.5-3.5 h), beginning 45 min after the completion fo cisplatin infusion. Peak total and ultrafiltrate levels and cisplatin pharmacokinetics in this study were indistinguishable from those of previous studies using the same HDCP regimen without DDTC rescue. Ultrafiltrate or unbound plasma platinum was<10% of total plasma platinum concentrations and demonstrated a biphasic pattern of elimination. Levels of DDTC predicted to be chemoprotective (>400 μM) were achieved with the dose and schedule used in this study. These data demonstrate that DDTC can be targeted to protective plasma concentrations without significantly altering plasma cisplatin pharmacokinetics and support the potential usefulness of DDTC as a rescue agent following HDCP therapy.

Original languageEnglish (US)
Pages (from-to)276-278
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume23
Issue number5
DOIs
StatePublished - May 1989
Externally publishedYes

Fingerprint

Ditiocarb
Cisplatin
Pharmacokinetics
Platinum
Plasmas
Therapeutics
Chelating Agents
Metabolites
Toxicity
Appointments and Schedules

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy : preliminary pharmacologic observations. / DeGregorio, Michael W.; Gandara, David R; Holleran, Walter M.; Perez, Edith A.; King, Charles C.; Wold, Howard G.; Montine, Thomas J.; Borch, Richard F.

In: Cancer Chemotherapy and Pharmacology, Vol. 23, No. 5, 05.1989, p. 276-278.

Research output: Contribution to journalArticle

DeGregorio, Michael W. ; Gandara, David R ; Holleran, Walter M. ; Perez, Edith A. ; King, Charles C. ; Wold, Howard G. ; Montine, Thomas J. ; Borch, Richard F. / High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy : preliminary pharmacologic observations. In: Cancer Chemotherapy and Pharmacology. 1989 ; Vol. 23, No. 5. pp. 276-278.
@article{786895beff544dc5b89cbc967a7fe078,
title = "High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations",
abstract = "Diethyldithiocarbamate (DDTC), a chelating agent that is a major metabolite of disulfuram, has been proposed as a potential rescue agent to reduce toxicity following high-dose cisplatin (HDCP) therapy. In the present study, we examined the pharmcologic interaction of HDCP and DDTC given as rescue therapy. Total plasma platinum and ultrafiltrate platinum pharmacokinetics and DDTC levels were determined in six patients with advanced malignancies who received a total of 11 cycles of HDCP with DDTC rescue. HDCP therapy (200 mg/m2 per cycle) consisted of 100 mg/m2 reconstituted in 250 cc 3{\%} saline and infused over 3 h on days 1 and 8 of each 28-day cycle. DDTC rescue at a dose of 4 gm/m2 was given by an i.v. infusion (duration 1.5-3.5 h), beginning 45 min after the completion fo cisplatin infusion. Peak total and ultrafiltrate levels and cisplatin pharmacokinetics in this study were indistinguishable from those of previous studies using the same HDCP regimen without DDTC rescue. Ultrafiltrate or unbound plasma platinum was<10{\%} of total plasma platinum concentrations and demonstrated a biphasic pattern of elimination. Levels of DDTC predicted to be chemoprotective (>400 μM) were achieved with the dose and schedule used in this study. These data demonstrate that DDTC can be targeted to protective plasma concentrations without significantly altering plasma cisplatin pharmacokinetics and support the potential usefulness of DDTC as a rescue agent following HDCP therapy.",
author = "DeGregorio, {Michael W.} and Gandara, {David R} and Holleran, {Walter M.} and Perez, {Edith A.} and King, {Charles C.} and Wold, {Howard G.} and Montine, {Thomas J.} and Borch, {Richard F.}",
year = "1989",
month = "5",
doi = "10.1007/BF00292403",
language = "English (US)",
volume = "23",
pages = "276--278",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy

T2 - preliminary pharmacologic observations

AU - DeGregorio, Michael W.

AU - Gandara, David R

AU - Holleran, Walter M.

AU - Perez, Edith A.

AU - King, Charles C.

AU - Wold, Howard G.

AU - Montine, Thomas J.

AU - Borch, Richard F.

PY - 1989/5

Y1 - 1989/5

N2 - Diethyldithiocarbamate (DDTC), a chelating agent that is a major metabolite of disulfuram, has been proposed as a potential rescue agent to reduce toxicity following high-dose cisplatin (HDCP) therapy. In the present study, we examined the pharmcologic interaction of HDCP and DDTC given as rescue therapy. Total plasma platinum and ultrafiltrate platinum pharmacokinetics and DDTC levels were determined in six patients with advanced malignancies who received a total of 11 cycles of HDCP with DDTC rescue. HDCP therapy (200 mg/m2 per cycle) consisted of 100 mg/m2 reconstituted in 250 cc 3% saline and infused over 3 h on days 1 and 8 of each 28-day cycle. DDTC rescue at a dose of 4 gm/m2 was given by an i.v. infusion (duration 1.5-3.5 h), beginning 45 min after the completion fo cisplatin infusion. Peak total and ultrafiltrate levels and cisplatin pharmacokinetics in this study were indistinguishable from those of previous studies using the same HDCP regimen without DDTC rescue. Ultrafiltrate or unbound plasma platinum was<10% of total plasma platinum concentrations and demonstrated a biphasic pattern of elimination. Levels of DDTC predicted to be chemoprotective (>400 μM) were achieved with the dose and schedule used in this study. These data demonstrate that DDTC can be targeted to protective plasma concentrations without significantly altering plasma cisplatin pharmacokinetics and support the potential usefulness of DDTC as a rescue agent following HDCP therapy.

AB - Diethyldithiocarbamate (DDTC), a chelating agent that is a major metabolite of disulfuram, has been proposed as a potential rescue agent to reduce toxicity following high-dose cisplatin (HDCP) therapy. In the present study, we examined the pharmcologic interaction of HDCP and DDTC given as rescue therapy. Total plasma platinum and ultrafiltrate platinum pharmacokinetics and DDTC levels were determined in six patients with advanced malignancies who received a total of 11 cycles of HDCP with DDTC rescue. HDCP therapy (200 mg/m2 per cycle) consisted of 100 mg/m2 reconstituted in 250 cc 3% saline and infused over 3 h on days 1 and 8 of each 28-day cycle. DDTC rescue at a dose of 4 gm/m2 was given by an i.v. infusion (duration 1.5-3.5 h), beginning 45 min after the completion fo cisplatin infusion. Peak total and ultrafiltrate levels and cisplatin pharmacokinetics in this study were indistinguishable from those of previous studies using the same HDCP regimen without DDTC rescue. Ultrafiltrate or unbound plasma platinum was<10% of total plasma platinum concentrations and demonstrated a biphasic pattern of elimination. Levels of DDTC predicted to be chemoprotective (>400 μM) were achieved with the dose and schedule used in this study. These data demonstrate that DDTC can be targeted to protective plasma concentrations without significantly altering plasma cisplatin pharmacokinetics and support the potential usefulness of DDTC as a rescue agent following HDCP therapy.

UR - http://www.scopus.com/inward/record.url?scp=0024543936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024543936&partnerID=8YFLogxK

U2 - 10.1007/BF00292403

DO - 10.1007/BF00292403

M3 - Article

C2 - 2539912

AN - SCOPUS:0024543936

VL - 23

SP - 276

EP - 278

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -